DLPA
precursor
Summary
"DL-Phenylalanine is marketed as a nutritional supplement for its putative analgesic and antidepressant activities. The putative analgesic activity of DL-phenylalanine may be explained by the possible blockage by D-phenylalanine of enkephalin degradation by the enzyme carboxypeptidase A. The mechanism of DL-phenylalanine's putative antidepressant activity may be accounted for by the precursor role of L-phenylalanine in the synthesis of the neurotransmitters norepinephrine and dopamine."
“Phenylalanine - Wikidoc.” Wikidoc.org, 2022, www.wikidoc.org/index.php/Phenylalanine.
Benefits
1.
increases beta-endorphin levels by blocking the degradation enzyme, carboxypeptidase A. [1]
2.
may increase available dopamine by providing the first-stage precursor phenylalanine. [2]
3.
may reduce withdrawal symptoms from addictive substances by inhibiting endorphin breakdown [3]
Deficiency Factors
dietary insufficiency
Access a list of other supplements that enhance the benefits of when you signup for a support plan.
ApplicationsAlcohol Detox, Burnout, Sugar Detox
Dosage Guidelines
500
1500
mg
500
mg
6000
mg
without food
Recommended Products
DLPA DL-Phenylalanine 375 mg - Source Naturals
Order from Amazon
D L-Phenylalanine 500 mg - Life Extension
Order from Amazon
See a list of verified product recommendations for when you signup for a support plan.
References
1.
Walsh. “Analgesic Effectiveness of D-Phenylalanine in Chronic Pain Patients.” Archives of Physical Medicine and Rehabilitation, vol. 67, no. 7, 2021, pubmed.ncbi.nlm.nih.gov/3524509/.
2.
Nutrient Metabolism. Elsevier, 2003, www.sciencedirect.com/book/9780124177628/nutrient-metabolism.
3.
Blum, Kenneth, et al. “Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality.” Clinical Medical Reviews and Case Reports, vol. 2, no. 12, 31 Dec. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4760695/, https://doi.org/10.23937/2378-3656/1410076.
Legend
Get Started
